

# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

## 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer (ICTHIC) – Virtual Edition 22 – 26 April 2021

### Program

## Thursday 22<sup>nd</sup> 2021

15:00 – 15:15

**Congress Opening: Anna Falanga, Benjamin Brenner, Alok Khorana**

15:15 – 16:30

### Special Session

### **COVID-19, cancer and thrombosis**

*Chairs: P. Gresele (Italy), A. Falanga (Italy)*

Lecture: **COVID-19 Associated Thrombosis-a year later**  
J. Connors (USA)

Lecture: **COVID-19 is an acquired vascular hemopathy**  
*D.M. Smadjia (France)*

### **Selected Abstract**


***OC-01 - Venous thromboembolic events during the first and second waves of Covid-19 in breast cancer patients treated in an outpatient day hospital***

C. Frere, B. Bournet, S. Gourgou, J. Fraisse, C. Canivet, J.M. Connors, L. Buscail, D. Farge, on behalf of the Groupe Francophone Thrombose et Cancer and the BACAP Consortium. (France, Canada)

***OC-02 - Khorana risk score at diagnosis of SARS-CoV-2 infection as a predicting tool for venous thromboembolic disease development, and overall mortality, in cancer patients***

C. López Jiménez, C. Blanco Abad, J.L. Catoya Villa, A. Gutiérrez Ortiz de la Tabla, D.S. Juliao Caamaño, L. Ortega Morán, M. Martín Jiménez, A. Muñoz Martín (Spain)

***OC-03 - Heparin treatment in COVID-19 patients is associated with reduced in-hospital mortality: findings from an observational multicenter study in Italy and a***



# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

## ***meta-analysis of 11 studies***

S. Costanzo, R. Parisi, G. de Gaetano, M.B. Donati, L. Iacoviello, A. Di Castelnuovo, on behalf of the COVID-19 RISK and Treatments (CORIST) collaboration (Italy)

16:30 – 17:00

## **Special Lecture**

*Chair: A. Falanga (Italy)*

*Introduction to Lecture: C. Rizzi (Italy)*

**Lecture: Are the new technologies useful to medicine or the opposite?**

*A. Remuzzi (Italy)*

## Friday 23<sup>rd</sup> 2021

15:00 – 15:30

## **Plenary Lecture**

### **6th Simon Karpatkin Memorial Lecture**

Chairs: A. Falanga (Italy); B. Brenner (Israel); A.A. Khorana (USA)

*Introduction to Lecture: F.R. Rickles (USA)*

***Lecture: Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer - past, present and future***

*I. Pabinger (Austria)*

15:30 – 17:00

## **Plenary Session 1**

### **New Insights In Prevalence of Cancer-Associated Thrombosis**

Chairs: H.A. Liebman (USA), M. Aapro (Switzerland)


***PL-01 - Screening for Occult Cancer: Where Are We in 2020?***

*L. Jara-Palomares (Spain)*

***PL-02 - An overview of thrombotic complications of old and new anti-cancer drugs***

*M. Levi (The Netherlands)*

***PL-03 - Impact of arterial thrombosis in cancer patients***



# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

S.C. Cannegieter (The Netherlands)

**PL-04 – Cancer associated thrombosis in pediatric setting**

G. Kenet (Israel)

**Selected Abstract**

**OC-04 - Incidence, Predictors and Clinical Outcomes of Venous Thromboembolism in Patients with Newly Diagnosed Pancreatic Ductal Adenocarcinoma: Results of the Prospective BACAP-VTE Study**

C. Frere, B. Bournet, S. Gourgou, J. Fraisse, C. Canivet, J.M. Connors, L. Buscail, D. Farge, on behalf of the Groupe Francophone Thrombose et Cancer and the BACAP Consortium. (France, Canada)

**OC-05 - Risk of venous thromboembolism in cancer patients: a cohort study**

F. Mulder, E. Horváth-Puhó, N. van Es, H.W.M. van Laarhoven, L. Pedersen, H.R. Büller, H.T. Sørensen (The Netherlands, Denmark)

17:00 – 17:30

**Roundtable**

**Risk assessment models for VTE in cancer**

*Chairs: P. Angchaisuksiri (Thailand), C. Ay (Austria)*

**Introduction: Overview of risk assessment models for VTE in ambulatory patients with cancer**

*G. Gerotziafas (France)*

**Discussants:** *N. Van Es (The Netherlands), A. Falanga (Italy), A.A. Khorana (USA), G. Gerotziafas (France), M.B. Donati (Italy)*

**Saturday 24<sup>th</sup> 2021**

11:00 – 11:30

**Poster Session 1: Prevention of thrombosis**

*Chair: L. Bertolletti (France)*


11:45 – 12:15

**Poster Session 2: Epidemiology I**

*Chair: E. Faioni (Italy).*

12:30 – 13:00

**Poster Session 3: Hypercoagulability in cancer**



# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

Chair: C.C. Kirwan (UK)

15:00 – 16:30

## **Plenary session 2**

### **Hematological malignancies**

Chairs: H. Ten Cate (The Netherlands), F. Rodeghiero (Italy)

#### ***PL-05- Risk-assessment of thrombosis and bleeding in hematological malignancies***

B. Brenner (Israel)

#### ***PL-06 - Advances in management of coagulopathy in APL***

M.A. Sanz (Spain)

#### ***PL-07 - Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia***

A. Leader (Israel)

#### ***PL-08- Multiple myeloma-associated VTE risk prediction***

K. Sanfilippo (USA)

### **Selected Abstract**

#### ***OC-06 - The Molecular Mechanisms of Ponatinib-Induced Thrombosis***

A.H. Schmaier, A.A. Merkulova, E.R. Chan, E.X. Stavrou, S.C. Mitchell, G.L. Forbes, P. Zeng (USA)

#### ***OC-07 - Differences in Thromboprophylaxis Between Hospitalized Patients with Solid or Hematological Malignancies***

R. Figueroa, M. Marcos-Jubilar, A. García-Mouriz, J.A. Páramo, R. Lecumberri (Spain)

16:30 – 17:00

## **Roundtable**


### **Emerging practical guidelines for the prevention and treatment of CAT**

Chairs: M. Cattaneo (Italy), R. Labianca (Italy)

#### ***Introduction: Overview of VTE treatment and prevention in cancer according to clinical guidelines***

G. Lyman (USA)

**Discussant:** A. Falanga (Italy), A. Lee (Canada), D. Farge (France), K. Jordan (Germany), I. Elalamy (France), G. Lyman (USA)



# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

17:00 – 18:45

## **Plenary Session 3**

### **Biomarkers in CAT and cancer progression**

Chairs: N. Mackman (USA), A.K. Olsson (Sweden)

#### ***PL-09 - Impact of preclinical variables on thrombotic biomarkers levels in cancer***

R. Selby (Canada)

#### ***PL-10 - Biomarkers in cancer VTE: Data from the AVERT study***

N. Key (USA)

#### ***PL-11 - Thrombotic biomarkers in occult cancer and cancer risk prediction***

M. Marchetti (Italy)

#### ***PL-12 - Genes and proteins associated with CAT risk***

H. Versteeg (The Netherlands)

#### ***PL-13 - Role of NETs in cancer associated-thrombosis***

S. Zeerleder (Switzerland)

## **Selected Abstract**

#### ***OC-08 - Biomarkers of venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis (HISPALIS- Study).***

R. Otero Candelera, V. Sánchez López, E. Arellano Orden, J. Oto Martinez, A. Solier-López, S. Marín Romero, L. Jara Palomares, T. Elias Hernández, M.I. Asencio Cruz, I. Blasco-Esquivias, M. Rodriguez de la Borbolla, J.M. Sánchez Díaz, F.J. Rodriguez Martorell, P. Medina Badenes (Spain)

#### ***OC-09 - Proteomic profiling in cancer-associated VTE***


M. Panova-Noeva, A. Schulz, T. Köck, V. ten Cate, B. Wagner, S. Rapp, M. Lenz, A. Zink, M. Ghadessi, S. Konstantinides, H. ten Cate, S. Heitmeier, P. Wild (Germany, The Netherlands)

## Sunday 25<sup>th</sup> 2021

11:00 – 11:30

### **Poster Session 4: Treatment of thrombosis**

Chair: A. Young (UK)



# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

11:45 – 12:15

**Poster Session 5: Epidemiology II**

Chair: A Federici (Italy)

12:30 – 13:00

**Poster Session 6: Therapeutic challenges**

Chair: M. Mandalà (Italy)

13:15 – 13:45

**Poster Session 7: Hemostatic system/tumor biology interactions**

Chair: M. Camera (Italy)

15:00 – 16:45

**Plenary Session 4**

**Bench to Bedside: New insights Into Hemostasis and Cancer**

Chairs: P.M. Sandset (Norway), R. Giavazzi (Italy)

***PL-14 - Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations***

J. Rak (Canada)

***PL-15 - Coagulation signaling and cancer immuno-therapy***

W. Ruf (Germany)

***PL-16 - Heparanase-revisited***

Y. Nadir (Israel)

***PL-17 - Mouse model of thrombosis and cancer***

C. Dubois (France)

***PL-18 - The thrombin-inflammation axis in cancer progression***


J. Palumbo (USA)

**Selected Abstract**

***OC-10 - Thrombin Tips the Scales towards Effective Immune Checkpoint Blockade in Cancer***

R. Cantrell, L. Rosenfeldt, D. Mureb, M. Lehn, B.K. Sharma, A. Revenko, B. Monia, E. Janssen, J.S. Palumbo (USA)

***OC-11 - Plasminogen activator inhibitor 1 and venous thrombosis in nude mice***



# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

## ***bearing human pancreatic tumors***

Y. Hisada, A. Maqsood, K. B. Garratt, B. C. Cooley, N. Mackman (USA)

16:45 – 17:15

### **Debate**

#### **Outpatient prophylaxis: are we there yet?**

Chairs: G. Agnelli (Italy), C. Francis (USA)

**NO:** F. Klok (The Netherlands)

**YES:** A.A. Khorana (USA)

17:15 – 18:30

### **Plenary Session 5**

#### **Prevention of VTE in cancer patients**

Chairs: P. Prandoni (Italy), J.A. Paramo (Spain)

#### ***PL-19 - Inpatient thromboprophylaxis in cancer patients: what is the evidence?***

J Zwicker (USA)

#### ***PL-20 - Roles of LMWH for prevention in cancer patients***

A Maraveyas (UK)

#### ***PL-21 - Meta-analysis and systematic review of NOAC prophylaxis in high risk cancer outpatients***

N. Kuderer (USA)

### **Selected Abstract**

#### ***OC-12 - D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial***

S. Vadhan-Raj, N. Kuderer, T. Wun, J. Patel, K. McCrae, X. Zhou, U. Vijapurkar, C.V. Damaraju, P. Wildgoose, G. Lyman, A.A. Khorana (USA)

#### ***OC-13 - A clinical-genetic risk score to predict cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts***

A. Muñoz, C. Ay, E. Grilz, S. López, C. Font, V. Pachón, V. Castellón, V. Martínez-Marín, M. Salgado, E. Martínez, J. Calzas, A. Rupérez, E. Salas, I. Pabinger, J.M. Soria (Spain, Austria)



# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

## Monday 26<sup>th</sup> 2021

11:00 – 11:30

### **Poster Session 8 - Thrombotic risk assessment**

*Chair: A.J. Ten Cate (The Netherlands)*

11:45 – 12:15

### **Poster Session 9 - Bleeding complications**

*Chair: E. De Candia (Italy)*

12:30 – 13:00

### **Poster Session 10 - New experimental and clinical approaches**

*Chair: E. Castoldi (The Netherlands)*

15:00 – 16:40

### **Plenary Session 6**

### **Evolving Data for Treatment of VTE in cancer**

*Chairs: G. Sof (USA), W. Ageno (Italy)*

#### ***PL-22 - Anticoagulation in Cancer Patients: advantages and disadvantages***

*A.J. Munoz (Spain)*

#### ***PL-23 - VTE management: emerging insights from the GARFIELD VTE registry***

*A.J. Kakkar (UK)*

#### ***PL-24 - Treatment of VTE in cancer patients: from clinical trials to real life***

*G. Agnelli (Italy)*

#### ***PL-25 - VTE in Palliative Care Patients: What do we know?***

*S. Noble (UK)*


### **Selected Abstract**

#### ***OC-14 - Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study***

*F.T.M. Bosch, T.F. Wang, M. Di Nisio, A. Segers, J. Connors, D. Garcia, F.I. Mulder<sup>1,2</sup>, J. Weitz, H.R. Büller, M. Carrier, P. Verhamme, M. Grosso, G. Raskob, N. van Es (The Netherlands, USA)*

#### ***OC-15 - Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study***





# 10<sup>th</sup> International Conference on Thrombosis & Hemostasis Issues in Cancer

F.X. Lapébie, A. Bura-Rivière, A. Merah, L. Bertoletti, M. Monreal, RIETE investigators  
(France, Spain)

***OC-16 - Apixaban as treatment for cancer-associated venous thrombosis - The CAP study***

T.L. Hannevik, J. Brekke, T. Enden, H. Frøen, H. Garresori, W. Ghanima, E.M. Jacobsen, P.Q. Paulsen, A.C. Porojnicu, A.H. Ree, P.M. Sandset, D. Torfoss, E.O. Velle, H.S. Wik, A.E.A. Dahm (Norway)

***OC-17 - Rivaroxaban versus Dalteparin for the Treatment of Cancer-Associated Venous Thromboembolism: the CASTA DIVA Trial***

Guy Meyer, Philippe Girard, Laurent Bertoletti, Anais Charles Nelson, Silvy Laporte, Isabelle Mahé, Olivier Sanchez, Patrick Mismetti, on behalf the CASTA DIVA Investigators (France)

16:40 – 17:10

**Debate**

**Incidental VTE: To treat or not to treat?**

Chairs: S. Siragusa (Italy), S. Middeldorp (The Netherlands)

**YES:** M. Di Nisio (Italy)

**NO:** M. Carrier (Canada)

17:10 – 17:25

**Concluding Remarks**